Adaptimmune Investment Portfolios

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Receives Consensus Rating of 'Moderate Buy' Mar 22, 2025

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Update Oct 31, 2024